Menu Back toSession-2-Track-C-Recently-Approved-Oligonucleotide-Drugs

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Session 2 Track C: Recently Approved Oligonucleotide Drugs

Session Chair(s)

G. Susan  Srivatsa, PhD

G. Susan Srivatsa, PhD

  • President
  • ElixinPharma, United States
This session will address the CMC challenges associated with the review and approval of inotersen and patisiran. Presentations will be followed by a panel discussion.


Jennifer A. Franklin, PhD

Strategies for Addressing Regulatory Agency Questions During Marketing Application Review for Oligonucleotides Drugs

Jennifer A. Franklin, PhD

  • Director, CMC RegulatoryAffairs
  • Ionis Pharmaceuticals, Inc., United States
Benjamin  Stevens, PhD, MPH

ONPATTRO® (Patisiran) A First-in-Class RNA Interference (RNAi) Therapeutic

Benjamin Stevens, PhD, MPH

  • Associate Director, Regulatory Affairs CMC
  • Alnylam Pharmaceuticals, United States
René  Thürmer, PhD


René Thürmer, PhD

  • Deputy Head of the Unit Pharmaceutical Biotechnology BfArM
  • Federal Institute for Drugs and Medical Devices, Germany
Lawrence  Perez, PhD


Lawrence Perez, PhD

  • Review Chemist
  • FDA, United States
Ian  Dobson


Ian Dobson

  • Team Leader, Evaluator
  • Health Canada, Canada